Cardax Pharmaceuticals is developing a platform of proprietary, exceptionally safe, small molecule compounds that impact inflammatory pathways affected by TNF-alpha, a major inflammatory cytokine. The Company’s pipeline includes its lead drug CDX-085 with application in metabolic syndrome, liver disease, and cardiovascular disease, as well as other proprietary prodrugs for macular degeneration and prostate disease.